Physician

Geetha J Kamath, MD

According to 2025 Medicare claims, Geetha Kamath, MD (NPI: 1669435004) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33709-2107.

Kamath's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 368 traditional Medicare patients, billed 230,702 HCPCS/CPT codes, and received $2,717,365 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,293 prescription claims across 209 beneficiaries totaling $3,536,516 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 18 claims. Open Payments data shows 128 records totaling $3,721. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $983,670 to $3,536,516. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,073 to $1,476.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	455	192,617	$1,930,229
2016	495	225,910	$2,182,853
2017	465	203,977	$2,887,365
2018	450	206,863	$2,880,896
2019	471	278,949	$3,153,742
2020	429	307,483	$3,875,772
2021	442	303,914	$3,466,426
2022	382	253,577	$3,126,839
2023	381	223,680	$2,282,785
2024	368	230,702	$2,717,365

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	170	1,363	$983,670
2016	205	1,253	$1,514,386
2017	204	1,125	$1,421,033
2018	193	1,209	$1,610,048
2019	196	1,138	$1,573,614
2020	195	1,183	$1,515,856
2021	240	1,235	$2,181,932
2022	223	1,228	$3,574,245
2023	210	1,166	$3,556,149
2024	209	1,293	$3,536,516

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	44	$998
2016	N/R	14	$441
2017	N/R	28	$6,809
2018	N/R	N/R	N/R
2019	N/R	14	$772
2020	N/R	N/R	N/R
2021	N/R	12	$43
2022	N/R	14	$45
2023	N/R	18	$1,330
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	241	770	$95
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	67	81	$13
96372	Injection of drug or substance under skin or into muscle	100	678	$11
36415	Insertion of needle into vein for collection of blood sample	275	1,454	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	261	1,475	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	39	1,108	$625,937
Pomalyst	Pomalidomide	26	728	$598,321
Verzenio	Abemaciclib	30	840	$396,592
Ibrance	Palbociclib	21	588	$333,144
Revlimid	Lenalidomide	13	364	$232,264

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	128	$3,721	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Geetha J. Kamath, MD?

Tedicare shows public-source Medicare data for Geetha J. Kamath, MD (NPI 1669435004), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Geetha J. Kamath, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Geetha J. Kamath, MD?

Geetha J. Kamath, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Geetha J. Kamath, MD have Open Payments data?

Geetha J. Kamath, MD has 128 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.